AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- CDH17 has shown promising pre-clinical efficacy without toxicity to healthy cells.
- Data published in Nature Cancer highlights tumor eradication in mouse models
- Phase 1/2 trial for CHM-CDH17 is focused on colorectal, gastric, and neuroendocrine cancers.
- The first patient has been enrolled for the Phase 1/2 multi-center trial for CHM CDH17 cell therapy.
Chimeric Therapeutics (ASX: CHM) is a clinical-stage cell therapy company. It is focused on advancing its three CAR T and NK assets in four clinical trials.
Image source: Company update
Led by an experienced team, Chimeric is advancing CHM-CDH17, the only CDH17 CAR-T in clinical trials globally. A report from Grand View Research highlighted that CHM CDH17 had a total global market size of AU$25.3 billion in 2023.
Image source: Company update
CHM CDH17 - First CDH17 targeting CAR-T in clinical trials
CDH17 is a protein prominently expressed on the surface of gastrointestinal cancers. The CDH17 CAR T cell therapy has demonstrated pre-clinical efficacy across a spectrum of cancers, including gastric, pancreatic, and neuroendocrine cancers. Pre-clinical models yielded encouraging results, showcasing complete tumour eradication in seven types of cancer. Moreover, the pre-clinical models demonstrated no toxicity in healthy cells.
Preclinical evidence for CDH17 CAR T was published in March 2022 in Nature Cancer. The publication demonstrated the complete eradication of tumors with no relapse in seven mouse models.
Chimeric has initiated the Phase 1/2 clinical trial, which aims to enroll 15 patients diagnosed with colorectal, gastric, and neuroendocrine cancers.
On 22 July 2024, the company announced the enrollment of first patient in the Phase 1/2 clinical trial.
Data source: company update
As the world's first CDH17 CAR T cell therapy to enter clinical trials, CDH17 CAR T is the culmination of over a decade of development at the University of Pennsylvania, a well-known center for cell therapy. Enrolling the first participant in the Phase 1/2 trial is a key milestone for the company.
CHM shares traded at AU$0.021 apiece on 29 July 2024.
